39
Participants
Start Date
April 30, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2031
XRD-0394
Administered orally; small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-PK.
Radiation Therapy
"For Cohort A and Cohort B, the neoadjuvant boost radiation dose is 1400cGy delivered over 7 fractions, and the adjuvant radiation dose is 5000cGy delivered over 25 fractions for a total dose of 6400cGy over 32 fractions, accounting for the treatment break between boost and adjuvant RT.~For Cohort C, the radiation dose is 3500cGy delivered over 10 fractions."
Surgical Resection
Resection of tumor tissue.
NYU Langone Health, New York
NYU Langone Health
OTHER